J. Levin

Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens

G. Gerken, K. Chayama, K. Reddy, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Retrospective analysis of hepatitis C infected patients treated through an integrated care model

M. Bauer, J. Levin, Shabnam Dabirshahsahebi, 2016, World journal of gastroenterology.

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.

V. de Lédinghen, P. Angus, K. Reddy, 2015, JAMA.

Fixed-Dose Combination TherapyWith Daclatasvir , Asunaprevir , and Beclabuvir for Noncirrhotic Patients With HCVGenotype 1 Infection

P. Angus, K. Reddy, B. Conway, 2015 .

Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1‐infected treatment‐naive patients

T. Hassanein, P. Thuluvath, G. Everson, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Haemophilia, hepatitis and porphyria

J. Burnett, J. Lamon, J. Levin, 1977, The British journal of dermatology.

In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents

F. Strle, J. A. Nelson, C. Benson, 1993, Antimicrobial Agents and Chemotherapy.

HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood.

J. Berzofsky, M. Clerici, H. Kessler, 1994, JAMA.

Clearance duration as a predictor of sustained viral response in patients with chronic hepatitis C virus genotype 1.

R. Striker, A. Said, M. Shenoy, 2005, The Journal of infectious diseases.

Epidemiology of Hepatitis A in Israel

T. Swartz, J. Levin, E. Ben‐Porath, 1984 .